01:32:05 EST Sat 25 Jan 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Pivot Pharmaceuticals Inc
Symbol PVOT
Shares Issued 88,679,077
Close 2019-08-19 C$ 0.36
Recent Sedar Documents

Pivot Pharmaceuticals appoints Rinow as CEO

2019-08-19 10:10 ET - News Release

Dr. Toni Rinow reports

PIVOT PHARMA APPOINTS TONI RINOW AS NEW CHIEF EXECUTIVE OFFICER

Pivot Pharmaceuticals Inc. has appointed Dr. Toni Rinow as chief executive officer and Dr. Wolfgang Renz as regional manager of Europe, in addition to serving as chief medical officer.

Under Dr. Rinow's leadership, Pivot will be put on a path of accelerated revenue growth and global expansion in key cannabis markets in Canada, the United States and the European Union. In combination with a solid merger-and-acquisition strategy, the organization will scale up to become a cannabis leader in the pharmaceutical, OTC (over-the-counter), nutraceutical and wellness markets.

A transformational finance and business leader with 20 years of experience, Dr. Rinow is a catalyst for growth and strategic global expansion in health care companies and well known for accelerating revenue streams through acquisitions, corporate development, sales and marketing, and financings. With a proven record in international corporate development and sales as well as financing of companies, she held leadership roles in public and private health care organizations up to $200-million in revenue, where she spearheaded acquisitions across Canada, Latin America, Europe and India.

In addition to her MBA from McGill University, she holds a doctorate (PhD) in physical chemistry from the Universite de Montreal and a chemical engineering degree from the European Higher Institute of Chemistry in Strasbourg, France. Dr. Rinow believes in giving back to the community and sits on the board of directors of several not-for-profit organizations.

Dr. Renz has been a leader for pharmaceutical corporations over the last two decades, delivering significant commercial successes by identifying and exploiting new business opportunities across the health care industry. Dr. Renz is former corporate vice-president of Boehringer Ingelheim GMBH, where he had global responsibility for new business models and health care innovation, developing the disruptive technologies that will shape the way health care will be delivered in the future. Dr. Renz's unique combination of medical expertise -- he is adjunct professor of experimental surgery on McGill University's faculty of medicine -- and global business acumen enables him to be effective in identifying and leading growth opportunities. Dr. Renz holds a medical degree and a PhD from Freiburg University and is board certified in Germany in emergency medicine.

"I am excited to be joining the Pivot team," commented Dr. Rinow. "Pivot is transformational to the cannabis market by bringing superior, science-based, high-quality and innovative products to the consumer market. With its focus on innovation and intellectual property, Pivot is well positioned to become a cannabis leader with the industry's largest portfolio of patented consumer cannabis products."

"On behalf of the board, I want to welcome Toni to Pivot. We are confident that with Toni's proven leadership skills and extensive experience within the global healthcare industry, she is well positioned to successfully lead us at home and abroad through the upcoming growth phase," commented Mr. Toth, executive chairman.

"It is exhilarating to speed up the European expansion," commented Dr. Renz. "With our high-quality products, we are well positioned to become a brand leader in the cannabis consumer, OTC, nutraceutical and pharmaceutical markets."

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals is a science-based, consumer packaged good cannabis company engaged in the development and commercialization of health and wellness products using innovative, patent-protected drug delivery technologies. Upon receipt of standard processor and medical sales licences (pending) from Health Canada, Pivot's premium, bioavailable, stable and effective products will be manufactured at its 50,000-square-foot cGMP (current good manufacturing practice) facility located in Montreal, Que. Pivot's product line will include infused beverages, vegan capsules, dissolvable tablets, topical creams and gels, intimate lubricants, roll-on pain relievers, stick packs, and bulk powder for the edibles market.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.